 |
burosumab |
|---|---|
| Trade Name | |
| Orphan Indication | X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets) |
| USA Market Approval | USA |
| USA Designation Date | 2009-12-14 00:00:00 |
| Sponsor | Ultragenyx Pharmaceutical, Inc.;60 Leveroni Court, Suite 200;Novato, California, 94949 |
